Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Cetuximab

Hypothyroidism, pneumonitis and rash

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Hui R, et al. The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma. Journal of Cancer 15 : 1668-1674, No. 6, Jan 2024. Available from: URL: https://dx.doi.org/10.7150/jca.92689 Hui R, et al. The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma. Journal of Cancer 15 : 1668-1674, No. 6, Jan 2024. Available from: URL: https://dx.doi.org/10.7150/jca.92689
Metadaten
Titel
Cetuximab
Hypothyroidism, pneumonitis and rash
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54797-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Naproxen

Case report

Metronidazole